DGAT2 (diacylglycerol O-acyltransferase 2) is a key enzyme in lipid metabolism, primarily responsible for catalyzing the final step of triglyceride synthesis by transferring a fatty acyl group from acyl-CoA to diacylglycerol. Unlike its isoform DGAT1. DGAT2 is embedded in the endoplasmic reticulum membrane and exhibits tissue-specific expression, with high activity in the liver, adipose tissue, and mammary glands. Its role in lipid storage and lipoprotein assembly makes it a critical target for studying metabolic disorders, including obesity, non-alcoholic fatty liver disease (NAFLᴅ), and type 2 diabetes. Dysregulation of DGAT2 has also been linked to cancer progression, as lipid droplets contribute to tumor cell survival under stress.
DGAT2 antibodies are essential tools for detecting and quantifying DGAT2 protein levels in research. These antibodies enable the investigation of DGAT2's expression patterns, subcellular localization, and regulatory mechanisms through techniques like Western blotting, immunohistochemistry, and immunofluorescence. High-specificity DGAT2 antibodies help distinguish it from DGAT1. minimizing cross-reactivity. Researchers use these antibodies to explore DGAT2's functional roles in metabolic pathways, evaluate its therapeutic potential in lipid-related diseases, and validate genetic or pharmacological interventions in preclinical models. Commercial DGAT2 antibodies are typically developed in rabbits or mice, with validation in human, mouse, or rat samples, ensuring broad applicability in translational studies.